Active research is expanding therapeutic options available to treat multiple myeloma. Our strategy is focused on using a novel vaccine design, a DNA cassette, to target myeloma-specific markers (or antigens) and elicit antitumor immune responses. In this proposal, we will use the observation that some antigens are common to germ cells and tumor cells. We will use emerging technology to carry out a genome wide comparison of germ cells and myeloma cells to identify genes which are expressed in both, but not in normal cells. This will allow a specific attack on myeloma antigens using our DNA vaccine.